Marginal Zone Lymphoma Pipeline and Clinical Trial Analysis: 50+ Players, 50+ Assets, and Key Clinical Breakthroughs, analyses DelveInsight

DelveInsight's "Marginal Zone Lymphoma Pipeline Insight" report delivers an in-depth analysis of more than 50 companies and 50+ investigational drugs shaping the Marginal Zone Lymphoma (MZL) pipeline ecosystem. The report comprehensively outlines Marginal Zone Lymphoma drug profiles, spanning both clinical-stage and non-clinical development programs.

It further evaluates the Marginal Zone Lymphoma therapeutic landscape based on product classification, development phase, route of administration, and molecular category. Additionally, the report identifies and examines inactive or discontinued pipeline assets within the Marginal Zone Lymphoma space.

Download DelveInsight's detailed Marginal Zone Lymphoma Pipeline Report to gain insights into emerging therapies, leading players, and the evolving treatment landscape @ Marginal Zone Lymphoma Pipeline Outlook - https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Marginal Zone Lymphoma Pipeline Report
• December 05, 2025 - Dr. Shayna Sarosiek, MD, initiated a clinical study to assess the safety and therapeutic potential of pacritinib in patients with Waldenström macroglobulinemia (WM). Although pacritinib has not yet received FDA approval for WM, it is currently approved for myelofibrosis. Study procedures include eligibility screening, on-site clinical visits, patient questionnaires, laboratory evaluations (blood and urine), imaging studies such as CT scans and X-rays, ECG assessments, and bone marrow biopsies and aspirations.
• December 04, 2025 - The University of Utah launched a Phase II clinical trial evaluating pirtobrutinib in combination with rituximab in adults diagnosed with previously untreated Marginal Zone Lymphoma.
• December 02, 2025 - Genmab announced the initiation of an open-label, multicenter clinical study investigating the safety and early efficacy of epcoritamab (EPKINLYTM) in Japanese patients with relapsed, progressive, or refractory B-cell lymphomas, as well as those achieving partial or complete responses following prior standard treatments. The trial is structured into two phases: a dose-escalation Phase I followed by an expansion Phase II.
• DelveInsight's Marginal Zone Lymphoma pipeline analysis highlights a highly active and competitive environment, with more than 50 organizations advancing 50+ therapeutic candidates for MZL treatment.
• Leading companies in the Marginal Zone Lymphoma domain include Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech, ADC Therapeutics, MEI Pharma, Genentech, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Celgene, IGM Biosciences, Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Celldex Therapeutics, TG Therapeutics, VelosBio, Newave Pharmaceutical, Boryung Pharmaceutical, Cellectar Biosciences, Bio-Path Holdings, Nurix Therapeutics, and several others.
• Notable Marginal Zone Lymphoma therapies under development include Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine (150 μg/kg), Copanlisib, Rituximab, Venetoclax, among others.

Explore DelveInsight's comprehensive pipeline evaluation for deeper insights into ongoing clinical progress @ Marginal Zone Lymphoma Clinical Trials and Studies - https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma (MZL) ranks as the second most prevalent indolent non-Hodgkin's lymphoma (iNHL). Marginal Zone Lymphoma is classified into three major subtypes: extranodalMarginal Zone Lymphoma, (EMZL) of mucosa-associated lymphoid tissue (MALT), splenic MZL (SMZL), and nodal MZL. Extranodal Marginal Zone Lymphoma can develop in nearly any extranodal organ, particularly those without native lymphoid tissue such as the stomach, intestines, thyroid, lungs, and skin.
The stomach is the most commonly affected site, with strong evidence linking Helicobacter pylori infection to gastric EMZL development.
Splenic Marginal Zone Lymphoma primarily originates from marginal zone memory B-cells located in the spleen, splenic hilar lymph nodes, bone marrow, and peripheral bloo

Emerging Marginal Zone Lymphoma Therapies
Tafasitamab - Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody targeting CD19. In 2010, MorphoSys acquired global development and commercialization rights from Xencor, Inc.
The therapy incorporates XmAb® Fc engineering technology, designed to enhance antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), thereby strengthening tumor cell elimination.
Tafasitamab is currently undergoing Phase III clinical evaluation for Marginal Zone Lymphoma.

Amdizalisib (HMPL-689) - HUTCHMED
Amdizalisib is a novel, selective PI3Kδ small-molecule inhibitor targeting a critical pathway in B-cell receptor signaling. The compound demonstrates favorable pharmacokinetic characteristics, including high oral bioavailability, moderate tissue penetration, and low systemic clearance. Clinical studies are ongoing across the U.S., Europe, China, and Australia in patients with relapsed or refractory NHL subtypes, including Marginal Zone Lymphoma.

Orelabrutinib - InnoCare Pharma
Orelabrutinib is a next-generation Bruton's tyrosine kinase inhibitor (BTKi) developed for oncologic and autoimmune indications. It has received NMPA approval in China for relapsed/refractory CLL/SLL and mantle cell lymphoma. The therapy is currently being evaluated in Phase II clinical trials for Marginal Zone Lymphoma.

EO2463 - Enterome
EO2463 is a first-in-class microbiome-derived peptide cancer vaccine composed of four peptides linked to B-cell lineage markers.
The vaccine is designed to stimulate the immune system to recognize malignant B cells as foreign, triggering a targeted cytotoxic immune response.
This approach aims to achieve comprehensive depletion of cancerous B lymphocytes responsible for NHL.

Key Insights from the Marginal Zone Lymphoma Pipeline Report
• The report delivers detailed intelligence on companies actively developing MZL therapies and the breadth of assets per organization.
• It categorizes pipeline candidates into early-, mid-, and late-stage development.
• The analysis includes both active and inactive (discontinued or dormant) programs.
• Pipeline drugs are assessed based on clinical phase, route of administration, molecular target, monotherapy versus combination use, mechanism of action, and molecular class.
The report also provides an in-depth review of strategic collaborations, licensing agreements, and funding activities influencing future market growth.

Gain expert insights into the latest Marginal Zone Lymphoma innovations with DelveInsight's in-depth analysis @ Marginal Zone Lymphoma Unmet Needs - https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marginal Zone Lymphoma Companies
Key contributors include Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech, ADC Therapeutics, MEI Pharma, Genentech, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Celgene, IGM Biosciences, Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Celldex Therapeutics, TG Therapeutics, VelosBio, Newave Pharmaceutical, Boryung Pharmaceutical, Cellectar Biosciences, Bio-Path Holdings, Nurix Therapeutics, and others.

Marginal Zone Lymphoma Therapeutic Assessment by Route of Administration
• Inhalation
• Intravenous
• Oral
• Subcutaneous
• Parenteral
• Intranasal
• Combination routes (IV/Oral/Subcutaneous)
• Not Applicable (NA)

Molecule Types Covered
• Antibodies
• Antisense Oligonucleotides
• Immunotherapies
• Monoclonal Antibodies
• Peptides
• Proteins
• Recombinant Proteins
• Small Molecules
• Stem Cell Therapies
• Vaccines

Download DelveInsight's latest report for strategic insights into future Marginal Zone Lymphoma drug development @ Marginal Zone Lymphoma Market Drivers, Barriers, and Future Perspectives - https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Marginal Zone Lymphoma Pipeline Report
• Geographic Coverage: Global
• Key Companies: Incyte, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech, ADC Therapeutics, MEI Pharma, Genentech, Novartis, AstraZeneca, Kite Pharma, Roche, and others
• Key Therapies: Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine, Copanlisib, Rituximab, Venetoclax, among others
• Therapeutic Assessment: Monotherapy, Combination Therapy, Mono/Combination
• Clinical Stages Covered: Discovery, Preclinical, Phase I, Phase II, Phase III

Access DelveInsight's exclusive pipeline intelligence today @ Marginal Zone Lymphoma Emerging Drugs and Major Companies - https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
• Introduction
• Executive Overview
• Marginal Zone Lymphoma: Disease Background
• Pipeline Therapeutics Overview
• Therapeutic Evaluation
• DelveInsight's Strategic Analysis
• Late-Stage Pipeline (Phase III)
• Mid-Stage Pipeline (Phase II)
• Early-Stage Pipeline (Phase I/II)
• Preclinical and Discovery Programs
• Inactive Pipeline Assets
• Key Companies and Products
• Unmet Needs and Market Barriers
• Future Outlook and Conclusions
• Analyst Perspectives
• Appendix
• About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.